Company profile · free preview

Amgen Inc.

AMGN · NASDAQ · Healthcare · Updated 10/23/2026

Revenue

$36.8B

Fiscal 2025

Net income

$7.7B

Fiscal 2025

Free cash flow

$8.1B

Fiscal 2025

Net cash / (debt)

—

Fiscal 2025

Five-year financials

Fiscal year20252024202320222021
Revenue$36.8B$33.4B$28.2B$26.3B$26.0B
Net income$7.7B$4.1B$6.7B$6.6B$5.9B
Diluted EPS—————
Operating cash flow$10.0B$11.5B$8.5B$9.7B$9.3B
Free cash flow$8.1B$10.4B$7.4B$8.8B$8.4B
Cash$9.1B$12.0B$10.9B$7.6B$8.0B
Total debt—————

Where the cash went

Cumulative, fiscal 2021–2025, straight from the reported cash-flow statements.

Reinvested in capex

12.0%

of operating cash flow

Returned to owners

—

of free cash flow (buybacks + dividends)

Diluted share count

—

change 2021–2025

Capital expenditure $5.9BBar width = share of $48.9B operating cash flow
Operating cash flow$48.9B
Capital expenditure($5.9B)
Free cash flow$43.0B
Share buybacks—
Dividends paid—
Acquisitions (net)—
Net debt issued / (repaid)—
Stock-based compensation (non-cash)—

"—" means a year didn't report that line, so no total is shown rather than an estimate.

SEC filings

  • 10-K · period 2025-12-312026-02-13EDGAR

Ask anything about Amgen Inc.'s filings

"What changed since last year?" "Where is the cash going?" Get answers drawn straight from the filings.

Start researching free

More companies